NFE2L2 and neoplasm: The Akt/mTORC1/Nrf2 signaling pathway is therefore a valuable therapeutic target for AMD [152, 153], while the Nrf2-miR-129-3p-mTOR axis may be a therapeutic target for autophagy and tumor resistance [154].